Vol. 14, Issue 8 (2025)

Author(s):
Devendra Devidas Talele, Jayashri A Tayade, Sachin Shrikrushna Rane, Rajesh Yadav Chaudhari and Vijay Raghunath Patil

Abstract:
This study reports the development and characterization of chitosan-based nanoparticles (CNPs) for the controlled delivery of Remogliflozin etabonate, addressing its pH-dependent solubility and bioavailability challenges. Nanoparticles were synthesized through ionic gelation using polyvinylpyrrolidone (PVP) as a crosslinker, achieving a mean particle size of 47-55 nm (SEM) and high encapsulation efficiency. XRD analysis confirmed amorphization of the drug within the matrix, while FTIR spectra verified successful polymer-drug interaction. The optimized formulation exhibited sustained release kinetics, with around 90% cumulative release over selected duration following anomalous transport (Korsmeyer-Peppas exponent: n=0.510) and Higuchi diffusion (R²=0.993). Swelling studies demonstrated pH-responsive behavior, with prolonged gastric retention. Accelerated stability studies showed no significant alterations in drug content and dissolution profile, or physicochemical properties. The developed CNP system presents a robust platform for enhancing the oral bioavailability of Remogliflozin etabonate through synergistic pH-modulated release, mucoadhesion, and controlled dissolution kinetics, with potential clinical applications in diabetes therapy.